摘要
目的通过观察重组人促红细胞生成素(rhEPO)对新生儿HIE的治疗效果评价其临床价值。方法取新生儿缺氧缺血性脑病(HIE)患儿50例,随机分为治疗组25例及观察组25例,治疗2周后对两组患儿进行NBNA评分,治疗后3个月随访进行发育指数(MDI/PDI)评估。结果与对照组相比,治疗组的NBNA评分及发育指数评估均明显升高,差异有统计学意义(P均<0.01)。结论 rh EPO对新生儿HIE的近期疗效和长期预后有重大意义。
Objective The effects of neonatal HIE treatment is to use rhEpo to evaluate its clinical value. Methods Fifty cases of HIE were randomly divided into treatment group （25 cases） and the observation group （25 cases）, after two weeks of treatment, two groups of children NBNA score 3 months after treatment follow-up development index （an MDI / PDI） assessment. Results To compared with the control group, the NBNA score of the treatment group and the development in- dex assessment are significantly higher, the difference was statistically significant （P 〈 0.01）. Conclusion rhEPO will bring great significance for neonatal HIE term efficacy and long-term prognosis
出处
《中国现代医生》
2012年第18期142-143,145,共3页
China Modern Doctor
